Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Literature
1.
Haddad A, Davis M, Lungman R (2007) The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 15:251–257PubMedCrossRef
2.
Riechelmann RP, Saad ED (2006) A systematic review on drug interactions in oncology. Cancer Investig 24:704–712CrossRef
3.
Riechelmann RP, Krzyzanowska MK, O’Carroll A et al (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer
4.
Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56:286–290PubMedCrossRef
5.
Riechelmann RP, Tannock IF, Wang L et al (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592–600PubMedCrossRef
6.
Norton PG, Baker GR (2007) Patient safety in cancer care: a time for action. J Natl Cancer Inst 99:579–580PubMedCrossRef
Metadata
Title
Drug combinations with the potential to interact among cancer patients
Author
Rachel P. Riechelmann
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0274-3

Other articles of this Issue 9/2007

Supportive Care in Cancer 9/2007 Go to the issue

Supportive Care International

End-of-life care for nursing home residents dying from cancer in Nova Scotia, Canada, 2000–2003

Original Article

Critical weight loss in head and neck cancer—prevalence and risk factors at diagnosis: an explorative study

Letter to the Editor

Re: Dying at home or in an institution: perspectives of Dutch physicians and bereaved relatives

Short Communication

Determining mucosal barrier injury to the oesophagus using CT scan

Original Article

Symptom clusters in cancer patients with bone metastases

Original Article

Personality and fatigue in patients with benign or malignant breast disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits